Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252005 · ClinicalTrials.gov registry record · Phase 2
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
A Phase 2 study of Deep Vein Thrombosis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 520
- Enrollment target
- 20
- Study locations
NCT00252005 is a Phase 2 study of Deep Vein Thrombosis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 520 participants, below the 7,910-participant average among 24 other Deep Vein Thrombosis trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00252005, a Phase 2 study of Deep Vein Thrombosis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 520 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or fondaparinux and vitamin K antagonist in the treatment of subjects with acute symptomatic deep-vein thrombosis.
Conditions Studied
Interventions
- DRUG Apixaban
Study Locations (20)
Other
- Local Institution - Graz
- Local Institution - Vienna
- Local Institution - Hradec Králové
- Local Institution - Karlovy Vary
- Local Institution - Ostrava
- Local Institution - Ostrava Poruba
New South Wales
- Local Institution - Caringbah
- Local Institution - Kogarah
- Local Institution - Randwick
Victoria
- Local Institution - Box Hill
- Local Institution - Clayton
- Local Institution - Melbourne
New Mexico
- Local Institution - Albuquerque
North Carolina
- Local Institution - Chapel Hill
Texas
- Local Institution - San Antonio
Virginia
- Local Institution - Fredericksburg
Washington
- Local Institution - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00252005
The ClinicalTrials.gov registry entry for NCT00252005 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 520 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,910-participant average among 24 other Deep Vein Thrombosis trials with a reported enrollment target (93% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Deep Vein Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which Apixaban is the first listed.
NCT00252005 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, New South Wales, Victoria.
Frequently Asked Questions
What is clinical trial NCT00252005 about?
NCT00252005 is a clinical study titled "Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study". The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or fondaparinux and vitamin K antagonist in the treatment of subjects with acut...
What is the current status of trial NCT00252005?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 520 participants. The study started on 2005-11. Estimated completion is 2007-02.
What conditions does trial NCT00252005 study?
This clinical trial studies the following conditions: Deep Vein Thrombosis.
What interventions are being tested in trial NCT00252005?
The interventions under investigation include: Apixaban (DRUG).
Who is sponsoring clinical trial NCT00252005?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00252005 being conducted?
This trial has 20 study locations across New Mexico, North Carolina, Texas, Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Deep Vein Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)
COMPLETED · Phase 2
-
Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma
COMPLETED · Phase 2
-
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
RECRUITING · NA
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Apixaban in Thrombocytopenia
RECRUITING · Early Phase 1
-
Non-invasive Venous Air Plethysmography Assessment of Venous Hemodynamics in Patients Suspected Deep Venous Obstruction Used in Conjunction With Intermittent Pneumatic Compression.
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.